Abstract
Carumonam is a new monobactam antibiotic with antibacterial activity against Gram-negative bacilli.
The antibacterial activity in vitro of carumonam was determined against 128 strains of clinical isolates, comparing it with those of cefoperazone and another monobactam antibiotic; aztreonam. Carumonam was more active than cefoperazone and as active as aztreonam against Escherichia coli and Klebsiella, with MIC's lower than 0.1 μg/ml.
Against Pseudomonas aeruginosa it was more active than cefoperazone and as active as aztreonam.
Carumonam was administered to five patients with urinary tract infection 0.5-1g twice a day by drip infusion for 6-9 days.
The clinical effects were good in three patients, fair in one patient, and unevaluable in one. As to bacteriological effects, organisms were replaced by Gram-positive cocci in three patients, persisted in one patient, and were eradicated in one patient.
No side effects nor abnormal laboratory findings were found.
